MXPA01008993A - Tratamiento de combinacion para depresion y ansiedad. - Google Patents

Tratamiento de combinacion para depresion y ansiedad.

Info

Publication number
MXPA01008993A
MXPA01008993A MXPA01008993A MXPA01008993A MXPA01008993A MX PA01008993 A MXPA01008993 A MX PA01008993A MX PA01008993 A MXPA01008993 A MX PA01008993A MX PA01008993 A MXPA01008993 A MX PA01008993A MX PA01008993 A MXPA01008993 A MX PA01008993A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
anxiety
depression
combination treatment
penetrant
Prior art date
Application number
MXPA01008993A
Other languages
English (en)
Inventor
Joseph Schmidt Christopher
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA01008993A publication Critical patent/MXPA01008993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invencion se refiere a un metodo para el tratamiento de depresion o ansiedad en un mamifero, incluyendo un humano, administrando al mamifero un antagonista del receptor NK-1 penetrante del SNC, por ejemplo, un antagonista del receptor de la sustancia P, en combinacion con un antagonista del receptor 5HT1D; tambien se refiere a composiciones farmaceuticas que contienen un vehiculo farmaceuticamente aceptable, un antagonista del receptor NK-1 penetrante del SNC, y un antagonista del receptor 5HT1D.
MXPA01008993A 2000-09-06 2001-09-05 Tratamiento de combinacion para depresion y ansiedad. MXPA01008993A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23025700P 2000-09-06 2000-09-06

Publications (1)

Publication Number Publication Date
MXPA01008993A true MXPA01008993A (es) 2004-11-10

Family

ID=22864516

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008993A MXPA01008993A (es) 2000-09-06 2001-09-05 Tratamiento de combinacion para depresion y ansiedad.

Country Status (6)

Country Link
US (1) US20020049211A1 (es)
EP (1) EP1186318A3 (es)
JP (1) JP2002121153A (es)
BR (1) BR0103913A (es)
CA (1) CA2356797A1 (es)
MX (1) MXPA01008993A (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material
HUP0401154A2 (hu) * 2001-07-20 2004-10-28 Pfizer Products Inc. NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
JP2006503858A (ja) * 2002-10-04 2006-02-02 メルク シャープ エンド ドーム リミテッド Ｎｋ−１受容体拮抗薬としてのアザ二環式アミン誘導体
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
EA200601461A1 (ru) * 2004-03-17 2007-02-27 Пфайзер Продактс, Инк. Новые производные бензил(иден)лактама
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
KR20080023680A (ko) 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
WO2013161871A1 (ja) * 2012-04-25 2013-10-31 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
EP0532527B1 (en) * 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
EP0540526B1 (en) * 1990-07-23 1994-12-28 Pfizer Inc. Quinuclidine derivatives
DK0573522T3 (da) * 1991-03-01 1995-03-06 Pfizer 1-Azabicyclo(3,2,2)nonan-3-aminderivater
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
DE69213451T2 (de) * 1991-06-20 1997-01-09 Pfizer Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
TW202432B (es) * 1991-06-21 1993-03-21 Pfizer
EP0607164B1 (en) * 1991-09-26 2002-05-02 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
CA2157117C (en) * 1993-03-04 1999-01-05 Manoj C. Desai Spirocyclic piperidine derivatives
DE69505362T2 (de) * 1994-03-26 1999-04-29 Smithkline Beecham Plc Biphenyl-derivate als 5ht1d antagonisten
GB9416972D0 (en) * 1994-08-23 1994-10-12 Smithkline Beecham Plc Carbon side chain/indole/indolene
WO1997003066A1 (en) * 1995-07-07 1997-01-30 Pfizer Pharmaceuticals Inc. Substituted benzolactam compounds as substance p antagonists
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
FR2744449B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ES2267153T3 (es) * 1996-10-07 2007-03-01 MERCK SHARP & DOHME LTD. Antagonistas del receptor nk-1 penetrantes del snc como agentes antidepresivos y/o antiansiedad.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists

Also Published As

Publication number Publication date
BR0103913A (pt) 2002-05-21
EP1186318A3 (en) 2003-03-26
CA2356797A1 (en) 2002-03-06
US20020049211A1 (en) 2002-04-25
EP1186318A2 (en) 2002-03-13
JP2002121153A (ja) 2002-04-23

Similar Documents

Publication Publication Date Title
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
MXPA02001306A (es) Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
EP1219622A3 (en) Pharmaceutical compositions for CNS and other disorders
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG105534A (en) 5ht1 means and method for the treatment of migraine
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
GB9917822D0 (en) Nmda antagonist
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
EP1192952A3 (en) Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima
TW200628476A (en) Azabenzoxazoles for the treatment of CNS disorders
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
EP1260221A3 (en) Combination treatment for depression and anxiety

Legal Events

Date Code Title Description
FA Abandonment or withdrawal